Adjusted analysis of the association of statin use with survival outcomes by treatment type (ibrutinib vs nonibrutinib arms)
| Treatment type . | Variable . | OS . | Pinteraction . | PFS . | Pinteraction . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Events/patients . | HR (95% CI) . | P value . | Events/patients . | HR (95% CI) . | P value . | ||||
| Ibrutinib arms | Statin use | .013 | .92 | <.001 | .09 | ||||
| No | 133/491 | 1 | 184/491 | 1 | |||||
| Yes | 42/218 | 0.63 (0.43-0.90) | 61/218 | 0.55 (0.40-0.76) | |||||
| Non-ibrutinib arms | Statin use | .003 | .126 | ||||||
| No | 181/502 | 1 | 363/502 | 1 | |||||
| Yes | 50/200 | 0.60 (0.43-0.84) | 134/200 | 0.84 (0.68-1.05) | |||||
| Treatment type . | Variable . | OS . | Pinteraction . | PFS . | Pinteraction . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Events/patients . | HR (95% CI) . | P value . | Events/patients . | HR (95% CI) . | P value . | ||||
| Ibrutinib arms | Statin use | .013 | .92 | <.001 | .09 | ||||
| No | 133/491 | 1 | 184/491 | 1 | |||||
| Yes | 42/218 | 0.63 (0.43-0.90) | 61/218 | 0.55 (0.40-0.76) | |||||
| Non-ibrutinib arms | Statin use | .003 | .126 | ||||||
| No | 181/502 | 1 | 363/502 | 1 | |||||
| Yes | 50/200 | 0.60 (0.43-0.84) | 134/200 | 0.84 (0.68-1.05) | |||||
Adjustment variables: diagnosis, age, sex, weight, ECOG PS, bulky disease ≥5 cm, time since initial diagnosis, comorbidity count, use of beta-blockers, calcium channel blockers, ACEIs/ARBs, and diuretics.